ArticleJournal of managed care & specialty pharmacy2025
Evaluating time to access opioid treatment for patients with insurance that requires the Safe & Effective Management of Pain prior authorization form vs others.
Article in Journal of managed care & specialty pharmacy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn 2016, the Safe & Effective Management of Pain (SEMP) organization created guidelines regarding how to safely and effectively ensure patients were being treated with opioids. Two insurance companies in West Virginia used the SEMP guidelines to create a prior authorization (PA) form. This form requires extensive information about the patient to be submitted and then reviewed, including those with cancer or being treated with palliative intent.
objectiveTo evaluate the potential delay in accessing opioid prescriptions for patients with cancer or in palliative care who are required to use a specific PA form.
methodsThis retrospective chart review used pharmacy claims for opioid prescriptions that were prescribed from the Edwards Cancer Institute and filled at Marshall Pharmacy beginning on January 1, 2022, to June 30, 2024. Prescriptions were stratified into 2 groups, those who had an approved claim by an SEMP-PA adherent insurance and those who were approved by another insurance that may or may not have required a different PA (non-SEMP). Turnaround time was evaluated from the moment the prescription was entered into Marshall Pharmacy's software to the moment it was ready to be dispensed to the patient.
resultsA total of 62 (45%) prescriptions were in the SEMP-PA group, and 77 (55%) did not require an SEMP-PA. The mean average turnaround time for the SEMP-PA group was 32.9 (SD = 67.6) hours and in the non-SEMP group was 6.23 (SD = 18.3) hours. The difference in turnaround time between both groups is 26.7 hours (
conclusionsThe SEMP-PA, after completion and approval, was associated with a significant increase in turnaround time for patients with cancer or for those being treated with palliative intent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.